Align Technology Launches Integrated Consumer and Professional Brand Campaign Focused on Invisalign ® Treatment for Kids and Teens
As the leader in digital orthodontics, Align has developed an extensive end-to-end portfolio that helps doctors treat a range of case types including the most complex cases, and growing patients and kids as young as 6.
Share
'We are proud to launch these complementary Invisalign ® brand campaigns about the kid and teen-friendly orthodontic solutions from the #1 doctor-recommended clear aligner brand, 1 ' said Kamal Bhandal, senior vice president, Global Brand, Consumer and Americas Marketing. 'Our new 'Invisalign for Kids' brand consumer campaign is designed to increase awareness with parents that Invisalign aligners are an effective solution for kids and educate parents about the benefits of Invisalign treatment for kids and teens, including Invisalign ® Palatal Expander System, Invisalign First™, Invisalign ® System with mandibular advancement, as well as Invisalign ® Virtual Care to help parents monitor progress – all designed to deliver predictable results and a positive experience for growing children.'
The aspects of Invisalign treatment, from Phase 1 to comprehensive Phase 2, to retention are designed for predictable results and a positive experience while addressing the unique needs of growing children. And with Invisalign aligners, children can enjoy their favorite foods, keep up their oral hygiene, maintain an active lifestyle, and smile and build their confidence.
At the same time, our companion Invisalign 'Growing Patients' professional campaign provides doctors with information and awareness about the dedicated range of Invisalign treatment options designed specifically for children and teens from well-established products such as Invisalign First™ aligners to the latest additions in the growing patient product portfolio, including the Invisalign ® Palatal Expander System and Invisalign ® System with mandibular advancement featuring occlusal blocks ('MAOB').
Doctors can use the Invisalign System to treat nearly any orthodontic case, from children through teens to adults, at the different stages of their growth. Even with some baby teeth, it may be the perfect time for children ages 6 to 10 to start Phase 1 orthodontic treatment. According to the American Association of Orthodontists ('AAO'), children should get screened by an orthodontist by age 7. 2
Phase 1 treatment takes advantage of a child's normal development to help bones in the face and mouth grow correctly and reduce the need for more extensive treatment later. Once most permanent teeth are in place, Phase 2 treatment focuses on ensuring teeth are in their proper place for a healthy bite and a pleasing appearance. 3
'As kids and teens age and grow, orthodontic treatment needs to address both tooth movement and dental facial orthopedic or skeletal movement,' said Dr. Mitra Derakhshan, executive vice president, chief clinical officer, Global Treatment Planning and Clinical Services. 'As the leader in digital orthodontics, Align has developed an extensive end-to-end portfolio that helps doctors treat a range of case types including the most complex cases, and growing patients and kids as young as 6. I believe our new 'Invisalign for Kids' brand and 'Growing Patients' campaigns will help increase confidence in Invisalign treatment for the largest segment of the orthodontic market and drive further adoption among growing patients.'
This latest announcement is part of Align's long-term investment in the growing patients' segment of the market which has included multiple innovation milestones over 20 million smiles.
Overview of Invisalign products for growing patients:
2008: Invisalign ® Teen – Teen specific features to address patient compliance, natural eruption of permanent teeth, and root-movement control – issues that are common in treatment of younger patients.
2017: Invisalign ® System with mandibular advancement – the first clear aligner solution designed for simultaneous Class II correction and alignment in growing tween and teen patients and Invisalign ® System with mandibular advancement featuring enhanced precision wings.
2018: Invisalign First™ – the first clear aligner treatment with features designed specifically to address a broad range of indications in mixed-dentition patients, including shorter clinical crowns, management of erupting dentition, and predictable dental arch expansion.
2023: Invisalign ® Palatal Expander System –Align's first direct 3D printed orthodontic device, provides a safe, comfortable, and clinically effective 4 alternative to traditional palatal expanders that require manually turning a screw in the device in the mouth daily to achieve skeletal expansion.
2025: Invisalign ® System with mandibular advancement featuring occlusal blocks – Align's first clear aligner product with integrated solid occlusal blocks that delivers predictable mandibular advancement. Invisalign occlusal blocks provide durability, improve engagement, and enable vertical opening to offer earlier advancement of the mandible in cases like Class II deep bite to improve treatment efficiency.
'Our commitment is to support our doctors in treating patients through every step of their journey – from first visit to a lasting smile. More than 28 years of anonymized data from more than 20 million Invisalign ® patients treated globally have helped Align develop our integrated suite of innovative products and solutions that enable doctors to treat patients over their continuum of care,' said Michael Smith, Align vice president, Product Management. 'This new integrated campaign highlights the unique product offerings within our growing patient portfolio and how we are innovating in digital orthodontics to empower doctors to transform smiles and change lives.'
1. Based on a global survey of 1,786 doctors (dentists and orthodontists who use clear aligners) by IQVIA in NA, EMEA, LATAM, and APAC. Data on File at Align Technology, as of June 30, 2022.
2. American Academy of Orthodontists. The Right Time: When Should Your Child See an Orthodontist? (https://aaoinfo.org/whats-trending/when-should-your-child-see-an-orthodontist/) Accessed 2/26/24.
3. American Academy of Orthodontists. Embarking on a Two Phase Orthodontic Adventure (https://aaoinfo.org/whats-trending/6-facts-about-two-phase-treatment/) Accessed 2/28/24.
4. Based on a survey in August 2023 in Canada of 10 Invisalign trained orthodontists who participated in the Invisalign Palatal Expander System Technical Design Assessment and have treated at least 1 patient age 6-11 years with IPE. Data on file at Align Technology, Inc. as of October 30, 2023.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Why Iovance Biotherapeutics Stock Plummeted Today
Key Points Investors were hardly pleased by the company's double miss on second-quarter results. At least its revenue guidance was in line with expectations. 10 stocks we like better than Iovance Biotherapeutics › Investors are typically quite harsh on publicly traded companies that don't make their quarterly estimates, a dynamic vividly on display Friday with biotech stock Iovance Biotherapeutics (NASDAQ: IOVA). The company published its second-quarter earnings after market close the previous day, and the market reacted by trading the stock down by more than 20%. Amtagvi leads the way Iovance, a commercial-stage biotech that's focused on cell therapies for cancer treatment, reported slightly under $60 million in revenue for the period, which was nearly double the $31 million it earned in the same quarter of 2024. All of this is derived from sales of two products: Amtagvi and Proleukin. The former was by far the company's star, with over $54 million in sales. The steep increase in sales didn't filter down into a net profit, however. In fact, Iovance's GAAP (generally accepted accounting principles) net loss deepened during the quarter, coming in at almost $112 million ($0.33 per share) from the year-ago deficit of $97 million. Also, analysts were expecting Iovance to boost its top line even more. Their consensus estimate for revenue was a shade over $67 million. As for net loss, they were modeling a deficit of only $0.28 per share. In its earnings release, Iovance nevertheless sounded a bullish note about the future of its two commercialized products. It quoted CEO Frederick Vogt as saying that "Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing authorized treatment center growth continues and large community practices begin treating patients." No move on revenue guidance Investors might have liked to see that statement bolstered by a guidance raise. However, Iovance stuck to its existing forecast of $250 million to $300 million anchored, of course, by Amtagvi. The company pointed out that this is the first full year of Amtagvi sales, implying the future should be much rosier for the product. Do the experts think Iovance Biotherapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Iovance Biotherapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Plummeted Today was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Wells Fargo Lowers Lululemon (LULU) PT to $225, Cites US, China Concerns
Lululemon Athletica Inc. (NASDAQ:LULU) is one of the most undervalued Canadian stocks to buy now. On August 4, Wells Fargo analyst Ike Boruchow lowered the firm's price target on Lululemon to $225 from $270, while maintaining an Equal Weight rating on the shares. The firm believes that Lululemon remains in a tough spot. Wells Fargo mainly pointed to 3 key concerns: the lack of US comparable sales visibility, China growth trajectory, and H2 2025 margin headwinds. The company's net revenue increased by 7% year-over-year in Q1 2025 to $2.4 billion. Diluted EPS were $2.60, which was a slight increase from $2.54 in Q1 2024. Performance varied across regions. Americas' net revenue in particular increased by 3%, while comparable sales decreased by 2%. In contrast, international net revenue surged by 19%, with comparable sales rising by 6%. Overall, company-wide comparable sales increased by 1%. A store employee in an athletic apparel store restocking merchandise. The company expanded its physical presence by adding 3 net new stores, which brought the total number of stores to 770. For Q2 2025, the company projects net revenue to be between $2.535 and $2.560 billion, which is a growth of 7% to 8%. Diluted EPS is expected to be in the range of $2.85 to $2.90. Lululemon Athletica Inc. (NASDAQ:LULU) designs, distributes, and retails technical athletic apparel, footwear, and accessories for women and men under the lululemon brand in the US, Canada, Mexico, China Mainland, Hong Kong, Taiwan, Macau, and internationally. While we acknowledge the potential of LULU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Why Nektar Therapeutics Stock Popped 6% on Friday
Key Points Investors were reacting to the biotech's second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper than the consensus. 10 stocks we like better than Nektar Therapeutics › Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today. This was well higher than the 0.8% gain posted by the S&P 500 index. Sweet results In its second quarter, Nektar booked total revenue of just under $11.2 million, which was less than half of the nearly $23.5 million in the same period of 2024. All of this derived from noncash royalty revenue connected to the sales of future royalties. This isn't unusual for a biotech without a commercialized product that depends on royalties and other payouts from partners. Nektar added that its cash and investments in marketable securities stood at just under $176 million at the end of the quarter (June 30). That, plus the roughly $107.5 million it should reap from a recent secondary share issue, should fund its operations into the first quarter of 2027. Meanwhile, the company's net loss for the second quarter was slightly over $39 million, or $2.78 per share. On average, analysts were projecting Nektar would book $9.7 million in revenue and a net loss of only $0.20 per share. I should note here that it can be challenging for even the most experienced professionals to estimate the results of biotechs that don't draw meaningful revenue from commercialized products. On a fast track All that said, there are several potential tailwinds for Nektar just now, and the company wasn't shy about itemizing them in its earnings release. Among the more promising is the U.S. Food and Drug Administration granting its Fast Track designation for rezpegaldesleukin, Nektar's investigational drug targeting severe-to-very-severe alopecia areata (a skin disorder). Do the experts think Nektar Therapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nektar Therapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Popped 6% on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
